{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:51:16Z","timestamp":1769637076989,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,10,6]],"date-time":"2011-10-06T00:00:00Z","timestamp":1317859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00198-011-1793-9","type":"journal-article","created":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T15:03:13Z","timestamp":1317826993000},"page":"1769-1778","source":"Crossref","is-referenced-by-count":44,"title":["Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension"],"prefix":"10.1007","volume":"23","author":[{"given":"G.","family":"Bianchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Czerwinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kenwright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Burdeska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. R.","family":"Recker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,6]]},"reference":[{"issue":"1","key":"1793_CR1","first-page":"27","volume":"17","author":"NIH Consensus Statement","year":"2000","unstructured":"NIH Consensus Statement (2000) Osteoporos Prev Diagn Ther 17(1):27\u201329","journal-title":"Osteoporos Prev Diagn Ther"},{"key":"1793_CR2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","volume":"18","author":"JA Cramer","year":"2007","unstructured":"Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023\u20131031","journal-title":"Osteoporos Int"},{"key":"1793_CR3","doi-asserted-by":"crossref","unstructured":"Landfeldt E, Str\u00f6m O, Robbins S, Borgstr\u00f6m F (2011) Adherence to treatment of primary osteoporosis and its association to fractures\u2014the Swedish Adherence Register Analysis (SARA). Osteoporos Int (in press)","DOI":"10.1007\/s00198-011-1549-6"},{"key":"1793_CR4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/ciia.2006.1.4.415","volume":"1","author":"J-Y Reginster","year":"2006","unstructured":"Reginster J-Y, Rabenda V (2006) Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 1:415\u2013423","journal-title":"Clin Interv Aging"},{"key":"1793_CR5","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1185\/030079905X74862","volume":"21","author":"R Emkey","year":"2005","unstructured":"Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895\u20131903","journal-title":"Curr Med Res Opin"},{"key":"1793_CR6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jbspin.2007.07.011","volume":"75","author":"P Hadji","year":"2008","unstructured":"Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303\u2013310","journal-title":"Joint Bone Spine"},{"key":"1793_CR7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","volume":"60","author":"A Cooper","year":"2006","unstructured":"Cooper A, Drake J, Brankin E, Investigators PERSIST (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896\u2013905","journal-title":"Int J Clin Pract"},{"key":"1793_CR8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","volume":"44","author":"J Barrett","year":"2004","unstructured":"Barrett J, Worth E, Bauss F (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44:951\u2013965","journal-title":"J Clin Pharmacol"},{"key":"1793_CR9","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838\u20131846","journal-title":"Arthritis Rheum"},{"key":"1793_CR10","first-page":"488","volume":"35","author":"JA Eisman","year":"2008","unstructured":"Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488\u2013497","journal-title":"J Rheumatol"},{"key":"1793_CR11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11914-009-0003-6","volume":"7","author":"P Geusens","year":"2009","unstructured":"Geusens P (2009) Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep 7:12\u201317","journal-title":"Curr Osteoporos Rep"},{"key":"1793_CR12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199","journal-title":"N Engl J Med"},{"key":"1793_CR13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","volume":"75","author":"DD Mellstr\u00f6m","year":"2004","unstructured":"Mellstr\u00f6m DD, S\u00f6rensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462\u2013468","journal-title":"Calcif Tissue Int"},{"key":"1793_CR14","unstructured":"Black D, Reid I, Cauley J, Boonen S, Cosman F, Leung PC, Lakatos P, Man Z, Cummings S, Hue T, Ruzycky M-E, Martinez R, Su G, Bucci-Rechtweg C, Eastell R (2010) The effect of 3 versus 6\u00a0years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON Pivotal Fracture Trial (PFT). J Bone Miner Res 25(Suppl. 1):1070. Available at http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=4781a020-dc3a-46be-b49d-f706b5509c4e . Accessed 13 January 2011"},{"issue":"Suppl.1","key":"1793_CR15","first-page":"S15","volume":"20","author":"D Felsenberg","year":"2009","unstructured":"Felsenberg D, Czerwinski E, Stakkestad J, Neate C, Masanauskaite D, Reginster JY (2009) Efficacy of monthly oral ibandronate is maintained over 5\u00a0years: the MOBILE LTE study. Osteoporos Int 20(suppl1):S15, Abstract OC32","journal-title":"Osteoporos Int"},{"key":"1793_CR16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/clinchem\/47.4.694","volume":"47","author":"P Garnero","year":"2001","unstructured":"Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694\u2013702","journal-title":"Clin Chem"},{"key":"1793_CR17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1373\/clinchem.2007.094953","volume":"54","author":"P Garnero","year":"2008","unstructured":"Garnero P, Vergnaud P, Hoyle N (2008) Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54:188\u2013196","journal-title":"Clin Chem"},{"key":"1793_CR18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","volume":"20","author":"A Cranney","year":"2009","unstructured":"Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD (2009) Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20:291\u2013297","journal-title":"Osteoporos Int"},{"key":"1793_CR19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut","year":"2004","unstructured":"Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"1793_CR20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2008.10.052","volume":"44","author":"AL Sebba","year":"2009","unstructured":"Sebba AL, Emkey RD, Kohles JD, Sambrook PN (2009) Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 44:423\u2013427","journal-title":"Bone"},{"key":"1793_CR21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.clinbiochem.2009.04.001","volume":"42","author":"JP Brown","year":"2009","unstructured":"Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, Dooley KC, Don-Wauchope A, Douville P, Hanley DA, Jamal SA, Josse R, Kaiser S, Krahn J, Krause R, Kremer R, Lepage R, Letendre E, Morin S, Ooi DS, Papaioaonnou A, Ste-Marie LG (2009) Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem 42:929\u2013942","journal-title":"Clin Biochem"},{"key":"1793_CR22","first-page":"853","volume":"66","author":"SE Papapoulos","year":"2007","unstructured":"Papapoulos SE, Schimmer RC (2007) Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 66:853\u2013858","journal-title":"Ann Rheum Dis"},{"key":"1793_CR23","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2165\/00003495-200666120-00005","volume":"66","author":"KF Croom","year":"2006","unstructured":"Croom KF, Scott LJ (2006) Intravenous ibandronate: in the treatment of osteoporosis. Drugs 66:1593\u20131601","journal-title":"Drugs"},{"key":"1793_CR24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00002018-200730090-00003","volume":"30","author":"W Strampel","year":"2007","unstructured":"Strampel W, Emkey R, Civitelli R (2007) Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 30:755\u2013763","journal-title":"Drug Saf"},{"key":"1793_CR25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14310\/horm.2002.1226","volume":"8","author":"PD Papapetrou","year":"2009","unstructured":"Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones 8:96\u2013110","journal-title":"Hormones"},{"key":"1793_CR26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","volume":"14","author":"S Klawansky","year":"2003","unstructured":"Klawansky S, Komaroff E, Cavanaugh PF Jr, Mitchell DY, Gordon MJ, Connelly JE, Ross SD (2003) Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14:570\u2013576","journal-title":"Osteoporos Int"},{"key":"1793_CR27","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"NB Watts","year":"2010","unstructured":"Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555\u20131565","journal-title":"J Clin Endocrinol Metab"},{"key":"1793_CR28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2008.09.012","volume":"44","author":"IR Reid","year":"2009","unstructured":"Reid IR (2009) Osteonecrosis of the jaw\u2014who gets it, and why? Bone 44:4\u201310","journal-title":"Bone"},{"key":"1793_CR29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/14740338.7.4.491","volume":"7","author":"SJ Wimalawansa","year":"2008","unstructured":"Wimalawansa SJ (2008) Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 7:491\u2013512","journal-title":"Expert Opin Drug Saf"},{"key":"1793_CR30","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s11999-009-0725-x","volume":"467","author":"AS Sayed-Noor","year":"2010","unstructured":"Sayed-Noor AS, Sj\u00f6d\u00e9n GO (2010) Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 467:1921\u20131926","journal-title":"Clin Orthop Relat Res"},{"key":"1793_CR31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.2009.03581.x","volume":"72","author":"CV Odvina","year":"2009","unstructured":"Odvina CV, Levy S, Rao S, Zerwekh JE, Sudhaker Rao D (2009) Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 72:161\u2013168","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1793_CR32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00002018-200932090-00002","volume":"32","author":"K Ing-Lorenzini","year":"2009","unstructured":"Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R (2009) Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 32:775\u2013785","journal-title":"Drug Saf"},{"key":"1793_CR33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","volume":"39","author":"EB Kwek","year":"2008","unstructured":"Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224\u2013231","journal-title":"Injury"},{"key":"1793_CR34","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","volume":"358","author":"BA Lenart","year":"2008","unstructured":"Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304\u20131306","journal-title":"N Engl J Med"},{"key":"1793_CR35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","volume":"22","author":"AS Neviaser","year":"2008","unstructured":"Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346\u2013350","journal-title":"J Orthop Trauma"},{"key":"1793_CR36","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/BF03346353","volume":"30","author":"P Lee","year":"2007","unstructured":"Lee P, van der Wall H, Seibel MJ (2007) Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 30:590\u2013597","journal-title":"J Endocrinol Invest"},{"key":"1793_CR37","first-page":"485","volume":"13","author":"RK Cheung","year":"2007","unstructured":"Cheung RK, Leung KK, Lee KC, Chow TC (2007) Sequential nontraumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 13:485\u2013489","journal-title":"Hong Kong Med J"},{"key":"1793_CR38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","volume":"89","author":"SK Goh","year":"2007","unstructured":"Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DTC, Howe TS (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349\u2013353","journal-title":"J Bone Joint Surg Br"},{"key":"1793_CR39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","volume":"47","author":"A Giusti","year":"2010","unstructured":"Giusti A, Hamdy NAT, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case\/case series studies. Bone 47:169\u2013180","journal-title":"Bone"},{"key":"1793_CR40","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.bone.2010.12.033","volume":"48","author":"A Giusti","year":"2011","unstructured":"Giusti A, Hamdy NAT, Dekkers OM, Ramautar SR, Dijkstra PDS, Papapoulos SE (2011) Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 48:966\u2013971","journal-title":"Bone"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-011-1793-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1793-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T15:57:43Z","timestamp":1593100663000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-011-1793-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["1793"],"URL":"https:\/\/doi.org\/10.1007\/s00198-011-1793-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,6]]}}}